The findings of these analyses of recent randomized clinical trials suggest that lixisenatide may be a good treatment option for optimizing glycemic control in T2DM patients unable to achieve their HbA1c glycemic target on basal insulin ±OADs, regardless of BMI. This evidence concerns the gene INS and type 2 diabetes mellitus.